ONCOLOGY Continuing Medical Education February 2010

CONTINUING MEDICAL EDUCATION

Program release date: February 15, 2010Program expiration date: February 15, 2011

CME Post-TestCME Post-Test and Evaluation

About the Activity

This activity is based on review articles in the journal ONCOLOGY. It is developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

If you haven't read this month's issue of ONCOLOGY or would like to review the articles online, click on the links below:

Monoclonal Antibodies in Advanced B-cell Lymphomas

HDAC Inhibitors in Cancer Care

Learning Objectives

Discuss mechanisms by which malignant lymphocytes can become resistant to monoclonal antibody therapy.

Highlight current clinical trials exploring the role of new monoclonal antibodies, drug-antibody conjugates, and radioimmunotherapeutics in management of difficult-to-treat B-cell malignancies.

Describe histone deacetylase (HDAC) inhibition as an epigenetic anticancer strategy.

Explain the importance of surrogate markers and biomarkers in assessing patient response to, and benefit from, HDAC inhibition.

Target Audience

This activity targets physicians in the fields of oncology and hematology.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Countinuing Medical Education through the joint sponsorship of CME LLC and The Oncology Group. CME LLC is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The CME LLC designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Compliance Statement

This activity is an independent educational activity under the direction of CME LLC. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions With Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity. However, CME LLC, the Grantor, and CMP Healthcare Media shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s), or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources. The opinions and recommendations presented herein are those of the author(s) and do not necessarily reflect the views of the provider or producer.

Financial Disclosures

Authors' disclosures of potential conflicts of interest are found on the first page of each article.

Copyright

Copyrights owned by CME LLC. Copyright 2009, CME LLC. All rights reserved.

Post-Test and Evaluation

CME post-test and evaluation are available online at www.cancernetwork.com/cme. If you achieve an 80% or higher on your online post-test, you will be able to complete the evaluation and print your CME certificate. If you have any difficulty accessing the post-test online, contact CME LLC (see contact information below) to have the forms sent to you.

Contact Information

We would like to hear your comments regarding this or other activities provided by CME LLC. Suggestions for future activities are also welcome. Contact us at: Address: Director, Continuing Medical Education CME LLC Harborside Financial Center Plaza 3, Suite 806 Jersey City, NJ 07311 Phone: 888-618-5781 Fax: 201-946-0700 e-mail: customer.service@CMELLC.com